EYDAP expands remuneration policy to cover general directors under Law 5301/2026
Bitget2026/10/08 12:34Eydap published a revised remuneration policy, effective Oct. 30, 2026, expanding coverage to certain General Directors and Directors. KPI-based variable pay cap for executive board members set at 30% of fixed pay; total variable pay capped at 35%. Policy adds a separate discretionary bonus for executive board members, capped at the gross equivalent of two monthly base salaries. General Directors’ variable pay capped at 25% of annual fixed pay; Directors capped at 20%, subject to annual KPI setting. Introduces malus and clawback tools, including deferral or repayment of variable pay tied to inaccurate information or serious misconduct. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eydap SA - Athens Water Supply & Sewage Co. published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.
- Eydap published a revised remuneration policy, effective Oct. 30, 2026, expanding coverage to certain General Directors and Directors.
- KPI-based variable pay cap for executive board members set at 30% of fixed pay; total variable pay capped at 35%.
- Policy adds a separate discretionary bonus for executive board members, capped at the gross equivalent of two monthly base salaries.
- General Directors’ variable pay capped at 25% of annual fixed pay; Directors capped at 20%, subject to annual KPI setting.
- Introduces malus and clawback tools, including deferral or repayment of variable pay tied to inaccurate information or serious misconduct.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
